HC Wainwright&Co.:上调rapt therapeutics(RAPT.US)评级,由中性调整至买入评级,目标价由10.00美元调整至10.00美元。RAPT Therapeutics(RAPT.US)公司简介:RAPT Therapeutics Inc是一家基于临床阶段的免疫学生物制药公司。它专注于发现、开发和商业化口服小分子疗法用于未满足需求的肿瘤和炎症疾病患者。该公司的管道产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.